Lenalidomide Market Report 2024 (Global Edition)

Global Lenalidomide Market Report 2024 Market Size Split by Type (5mg, 10mg, 15mg, 25mg), by Application (Multiple Myeloma [MM], Myelodysplastic Syndromes [MDS]), by End-user (Hospitals, Cancer Treatm...

Lenalidomide Market Report Description

We have various report editions of Lenalidomide Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Lenalidomide Market Insights Video

Competitive Landscape of the Lenalidomide Market

The competitive landscape of the Lenalidomide Market is defined by a number of pharmaceutical businesses that manufacture and distribute the drug. These companies compete based on product quality, pricing, distribution network, and R&D initiatives. Accord Healthcare, Cipla, Deva Pharma and Dr. Reddy's Laboratories Ltd. are among the leading market players. These firms are actively invested in research, clinical trials, and marketing in order to maintain their market position and meet the growing demand for Lenalidomide in a variety of therapeutic applications.

In September 2022, Dr. Reddy's Laboratories Ltd. has launched lenalidomide capsules, a generic version of REVLIMID (lenalidomide) capsules, following FDA approval. This strategic action gave Dr. Reddy first-to-market status and 180 days of exclusivity for generic lenalidomide capsules in 2.5 mg and 20 mg dosages. (Source: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-revlimid-in-us-market/articleshow/94069505.cms?from=mdr) In March 2023, Teva Pharmaceuticals, in conjunction with NATCO Pharma Limited, has announced new dose options for the generic form of Revlimid (lenalidomide capsules) in the US. The new dosage strengths are 2.5 mg and 20 mg. (Source: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-additional-strengths-of-generic-version-of-revlimid-in-us/articleshow/98538080.cms?from=mdr)

Top Companies Market Share in Lenalidomide Industry: (In no particular order of Rank)

• Accord Healthcare
• Cipla
• Deva Pharma
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals
• Hetero
• Hikma Pharmaceuticals
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Lenalidomide Market

Which Region Dominates the Lenalidomide Market in 2024?

According to Cognitive Market Research, In 2023, North America held the most share. The presence of larger competitors in the lenalidomide industry has contributed significantly to its expansion. For example, in September 2022, Dr. Reddy Laboratories Ltd. launched Revlimid capsules (lenalidomide) in the United States after getting FDA permission. One of the primary factors leading to the increased market share in the worldwide market is the growing number of companies entering it.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is predicted to be the fastest expanding, with a higher CAGR, during the projection period, owing to the region's increasing cancer prevalence. Cancer is one of the world's leading causes of death, accounting for over 10 million fatalities. According to the WHO South-East region study, there are an estimated 2.2 million new cancer cases and 1.4 million cancer-related death rates, accounting for more than one in every ten deaths in the region. With the region's increasing cancer incidence, there will be a large demand in the future.

 

The current report Scope analyzes Lenalidomide Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Lenalidomide

According to Cognitive Market Research, the global Lenalidomide market size was estimated at USD 19584.5 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 7833.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Lenalidomide market with a market size of USD 6180.87 million in 2024 and is projected to grow at a CAGR of 3.5% during the forecast period. The US has historically held a significant share in the Lenalidomide market, driven by factors such as a high prevalence of cancer advanced healthcare infrastructure.
• The Canadia lenalidomide market had a market share of USD 940.06 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. Canada has a well-established healthcare system, and the demand for Lenalidomide in treating various cancers and hematological disorders contributes to the market growth in the country.
• The Mexico Lenalidomide market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 712.88 million in 2024.

Europe Lenalidomide

According to Cognitive Market Research, the global Lenalidomide market size was estimated at USD 19584.5 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 5875.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.0% from 2024 to 2031.

• The United Kingdom Lenalidomide market had a market share of USD 987.06 million in 2024 and is projected to grow at a CAGR of 4.8% during the forecast period. In the UK, Lenalidomide sales witness an upswing due to the advanced healthcare infrastructure.
• The France Lenalidomide market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 540.53 million in 2024.
• According to Cognitive Market Research, the Germany Lenalidomide market size was valued at USD 1163.32 million in 2024 and is projected to grow at a CAGR of 4.2% during the forecast period. In Germany, Lenalidomide sales surged due to the increasing prevalence of multiple myeloma.
• The Italy Lenalidomide market is projected to witness growth at a CAGR of 3.4% during the forecast period, with a market size of USD 505.28 million in 2024.
• The Russia Lenalidomide market is projected to witness growth at a CAGR of 3.0% during the forecast period, with a market size of USD 910.68 million in 2024.
• The Spain Lenalidomide market is projected to witness growth at a CAGR of 3.1% during the forecast period with a market size of USD 481.78 million in 2024
• The Luxembourg Lenalidomide market is projected to witness growth at a CAGR of 4.1% during the forecast period, with a market size of USD 182.14 million in 2024.
• The Portugal Lenalidomide market is projected to witness growth at a CAGR of 3.8% during the forecast period, with a market size of USD 123.38 million in 2024.
• The Greece Lenalidomide market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 70.50 million in 2024.
• Rest of Europe's Lenalidomide market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 910.68 million in 2024.

Asia Pacific Lenalidomide

According to Cognitive Market Research, the global Lenalidomide market size was estimated at USD 19584.5 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 4504.44 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Lenalidomide market size was valued at USD 2027.00 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Lenalidomide sales surge in China due to the growing awareness about the medication's effectiveness in treating multiple myeloma and other hematological disorders.
• The Japan Lenalidomide market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 621.61 million in 2024.
• The India Lenalidomide market had a market share of USD 540.53 million in 2024 and is projected to grow at a CAGR of 9.3% during the forecast period. In India, the Lenalidomide market is growing significantly due to the rising prevalence of multiple myeloma and other hematological disorders.
• The South Korean lenalidomide market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 450.44 million in 2024.
• The Australia Lenalidomide market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 234.23 million in 2024.
• The South East Asia Lenalidomide market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 310.81 million in 2024.
• The Rest of Asia Pacific Lenalidomide market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 319.81 million in 2024.

South America Lenalidomide

According to Cognitive Market Research, the global Lenalidomide market size was estimated at USD 19584.5 Million out of which the Latin America market of more than 5% of the global revenue with a market size of USD 979.23 million in 2024. It will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Lenalidomide market size was valued at USD 419.11 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. In Brazil, Lenalidomide sales flourish due to the increasing prevalence of multiple myeloma and other hematological disorders in the country.
• Argentina Lenalidomide market had a market share of USD 164.51 million in 2024 and is projected to grow at a CAGR of 5.8% during the forecast period. In Argentina, the Lenalidomide market is expanding due to several factors. The increasing incidence of hematological disorders, particularly multiple myeloma, has led to a growing demand for advanced treatments like Lenalidomide in the country.
• Colombia Lenalidomide market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 87.15 million in 2024.
• Peru Lenalidomide market is projected to witness growth at a CAGR of 5.1% during the forecast period with a market size of USD 80.30 million in 2024.
• Chile Lenalidomide market is projected to witness growth at a CAGR of 5.2% during the forecast period with a market size of USD 70.50 million in 2024.
• The Rest of Latin America Lenalidomide market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 157.66 million in 2024.

Middle East and Africa Lenalidomide

According to Cognitive Market Research, the global Lenalidomide market size was estimated at USD 19584.5 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 391.69 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

• The GCC Countries Lenalidomide market is projected to witness growth at a CAGR of 6.0% during the forecast period with a market size of USD 167.64 million in 2024. Lenalidomide sales flourish due to the increasing prevalence of hematological disorders.
• The Egypt Lenalidomide market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 41.13 million in 2024.
• The South Africa Lenalidomide market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 61.89 million in 2024. Lenalidomide sales flourish in South Africa due to growing awareness about advanced treatment options.
• The Turkey Lenalidomide market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 33.69 million in 2024.
• The Nigeria Lenalidomide market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 41.13 million in 2024.
• The Rest of MEA Lenalidomide market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 46.22 million in 2024.

Lenalidomide Market Analysis

Lenalidomide Market Type Segment Analysis

According to Cognitive Market Research, in 2023, the 15-mg segment had the most revenue share in the industry market, owing primarily to its capacity to aid doctors in establishing ideal treatment dosages for patients.

The 10mg sector is expected to increase at a greater CAGR during the research period, owing mostly to its dose flexibility. In some circumstances, doctors are needed to evaluate the patient's condition for malignancy and will likely start with a lower dose to avoid overdosing. This is increasing the usage of 10mg myeloma. Furthermore, the introduction of combination medicines to the market and continuous research activities are favorably supporting segmental growth, as this work involves the use of lower-dose pharmaceuticals.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Lenalidomide Industry. Request a Free Sample PDF!

Lenalidomide Market Application Category Segment Analysis

According to Cognitive Market Research, the multiple myeloma segment had the biggest market share in 2023 and is predicted to improve its market position during the study period. The increased prevalence of cancer cases, particularly multiple myeloma, and the higher efficacy of lenalidomide in treating these diseases are driving lenalidomide market expansion.

Myelodysplastic Syndromes (MDS) is the fastest growing category in the Lenalidomide Market, owing to the effectiveness of Lenalidomide in treating MDS. Lenalidomide, a medicine used to treat a variety of blood disorders, has demonstrated great success in controlling MDS, a category of disorders in which the bone marrow fails to create enough healthy blood cells. The rising prevalence of MDS cases, as well as the excellent outcomes seen with Lenalidomide treatment, have led to this segment's rapid market expansion.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Lenalidomide End-user Segment Analysis

End-user Segment Analysis

According to Cognitive Market Research, the hospital category had a considerable market share in revenue in 2023, which is rapidly increasing due to the growing number of cancer patients seeking admission. The increased knowledge of cancer, particularly blood cancer, is driving doctor visits and increasing demand for lenalidomide among healthcare practitioners.

Cancer Treatment Centers are the fastest expanding section of the Lenalidomide Market. Lenalidomide has demonstrated great efficacy in the treatment of a variety of malignancies, including multiple myeloma and certain kinds of lymphoma. Lenalidomide is in high demand in cancer treatment centers due to its demonstrated efficacy in cancer therapy.

• Hospitals
• Cancer Treatment Centers
• Research Institutes

Author's Detail

David Fuller

Senior Analyst at Cognitive Market Research

LinkedIn

Profile

I am working as a Senior Analyst with Cognitive Market Research in the areas of Industry Survey and Market Research/Analytics. I collaborate with CXOs, VPs, and other senior executives to understand their data needs and provide solutions and business strategy building.

Author's Conclusion